Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | GRK6 | P43250 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69492 | 0.83 | MEN1 (0.58) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL14501943 | 0.82 | MAPT (0.50) | CA12MEN1KMT2AMAPTALPL | |
| SCHEMBL2460252 | 0.82 | ALPL (0.60) | CA12MEN1KMT2APOLBALPL | |
| Hydrochloric Acid SCHEMBL1221862 | 0.82 | MEN1 (0.57) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL70360 | 0.78 | CA12 (0.53) | CA12MEN1KMT2APOLBMAPT | |
| SCHEMBL73351 | 0.78 | MEN1 (0.53) | CA12MEN1KMT2APOLBMAPT | |
| SCHEMBL3682308 | 0.76 | KMO (0.55) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL19996893 | 0.76 | MEN1 (0.50) | CA12MEN1KMT2APOLBMAPT | |
| SCHEMBL1413865 | 0.76 | ALPL (0.53) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL1413993 | 0.76 | HCAR2 (0.55) | MEN1KMT2APOLBMAPTHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2212321-A2 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | Memory Pharmaceuticals Corporation (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009055437-A9 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARM CORP (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009055437-A2 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | CHRNA7, CHRNA6, CHRNA5 | CA12 4828/4885MEN1 2161/4885KMT2A 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.